{"organizations": [], "uuid": "70d425c253e4cb09287c24330ac0b16d409026a0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fennec-pharmaceuticals-receives-br/brief-fennec-pharmaceuticals-receives-breakthrough-therapy-designation-by-fda-for-pedmark-idUSASC09TQI", "country": "US", "domain_rank": 408, "title": "BRIEF-Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.918, "site_type": "news", "published": "2018-03-27T19:44:00.000+03:00", "replies_count": 0, "uuid": "70d425c253e4cb09287c24330ac0b16d409026a0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fennec-pharmaceuticals-receives-br/brief-fennec-pharmaceuticals-receives-breakthrough-therapy-designation-by-fda-for-pedmark-idUSASC09TQI", "ord_in_thread": 0, "title": "BRIEF-Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fennec pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Fennec Pharmaceuticals Inc:\n* FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™\n* FENNEC PHARMACEUTICALS INC - ‍FDA GRANTED PEDMARK BREAKTHROUGH THERAPY DESIGNATION FOR PREVENTION OF CISPLATIN-RELATED OTOTOXICITY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T19:44:00.000+03:00", "crawled": "2018-03-28T19:23:20.037+03:00", "highlightTitle": ""}